Who Owns Your Supplement Formula?
Most founders discover the answer at the worst possible moment — when they want to leave their manufacturer and find out the product cannot come with them.
Short answer
Ownership is determined by the agreement you signed, not by how much of the formula was your idea. Under a standard private label arrangement the supplier owns the formula and you own the brand on the label. Under a contract manufacturing arrangement it varies enormously, and "we developed it together" is not a legal position. Three documents decide whether you can actually leave: the formula specification itself, the master batch record, and the supporting analytical and stability data. If the manufacturer owns the batch record, a second factory has to recreate it from scratch, which costs months and often requires re-doing stability work. Establish ownership of all three in writing before production, because the leverage to negotiate it disappears the moment you have inventory, customers, and reviews attached to a product only one facility knows how to make.
What are you actually trying to own?
"The formula" is not one asset. It is three, and a contract can assign them differently — which is how founders end up owning something that does not let them do the thing they wanted ownership for.
The formula specification
The composition itself: actives, doses, standardization, excipients, at input weight and finished dose. This is the asset most agreements address explicitly, and the one founders assume is the whole picture.
The master batch record
The manufacturing instruction set — steps, equipment, in-process checks, signature points. This is the asset that determines mobility. You can own a formula outright and still be unable to move, because a second manufacturer receiving only a composition has to develop the process from scratch: their equipment, their blend times, their compression parameters, their validation.
If a supplier is relaxed about formula ownership but firm about the batch record, they have understood the leverage better than you have.
The evidence package
Analytical methods, specification ranges, stability data, and any substantiation behind your label claims. Stability work in particular takes real time to redo — months of it — and a new manufacturer will often want their own. Owning the existing dataset at least gives you a starting point and a comparison.
The test: if you served notice tomorrow, what would you be entitled to receive, in what format, and could a second manufacturer make the same product from it? If you cannot answer that from the contract, you do not know what you own.
What ownership looks like under each model
| Private label | Modified stock base | Contract manufacturing | Formula you developed | |
|---|---|---|---|---|
| Formula specification | Supplier | Usually supplier | Negotiable | You |
| Master batch record | Supplier | Supplier | Frequently supplier | Negotiable, ask explicitly |
| Can a second factory make it | No | Rarely | Sometimes, with rework | Yes |
| Supplier can sell it to others | Yes | Often | No | No |
| Realistic switching cost | Reformulate | Reformulate | Recreate process | Transfer documentation |
The column that matters is the one describing what happens when you want to leave. Everything else is a description of the honeymoon.
What to put in writing before production
These belong in the manufacturing agreement, not in an email thread.
- Who owns the formula specification, stated explicitly rather than implied by silence.
- Who owns the master batch record, and what you receive if the relationship ends.
- Whether the manufacturer may produce the same or a materially similar formula for another brand.
- Who owns analytical methods, specification ranges, and stability data generated during development.
- What is handed over on termination, in what format, and within what period.
- Whether development work is billed separately, since paid development strengthens an ownership claim.
- Confidentiality that survives termination, not just during the relationship.
A manufacturer who agrees to these readily is not giving anything away — they are confident you will stay for the quality of the work rather than the cost of leaving. That is the partner you want.
Ownership is not the same as protection
Two things are worth separating, because they get conflated constantly and the confusion is expensive.
- Ownership means you control the formula: you can make it, change it, move it, and stop anyone under contract to you from selling it elsewhere. This is contractual, and it is achievable for essentially any formula.
- Protection means stopping a third party who never contracted with you from making something similar. That requires a patent, and most combinations of known botanical actives at conventional doses will fail the novelty and non-obviousness tests. Trade secret is the more realistic route for a formula, and it depends entirely on the confidentiality terms above.
Formulaite includes a novelty assessment precisely so you know which of the two you are dealing with before you spend money finding out. For most brands the honest answer is that the defensible asset is ownership plus the evidence package, not a patent — and that is a perfectly good position, as long as nobody built a plan on the other one.
Frequently asked questions
I paid for development. Doesn't that mean I own it?
Not automatically. Paying for development strengthens the argument considerably, and it is a reason to insist on ownership terms, but the contract governs. Plenty of agreements bill development work and still assign the resulting formula and batch record to the manufacturer. Read what you signed rather than reasoning from what feels fair.
Can I take my formula to a second manufacturer?
If you own the specification, the master batch record, and the analytical documentation, yes — that is what technology transfer is. If you own only the specification, the second factory has to develop the process, which is slower and may produce a product that behaves differently enough to need new stability data. If you own none of it, you are reformulating.
Should I patent my supplement formula?
Usually the honest answer is no, because most botanical combinations at conventional doses are neither novel nor non-obvious, and the process costs real money to discover that. Where genuine novelty exists — an unusual combination with a demonstrable unexpected effect, or a specific delivery approach — it is worth assessing properly. Run the novelty question before the patent budget, not after.
How does Formulaite handle formula IP?
The formula is generated for you and belongs to you, along with the manufacturer-ready documentation and the master batch record produced from the same source. That means the package you take to a manufacturer is one you already own, so ownership is not something you have to negotiate back after the fact — which is the position most founders find themselves in.
Related founder resources
Start from a formula you already own
Formulaite develops the formula, the brief, and the master batch record as one package that belongs to you — so changing manufacturers is a transfer, not a reformulation.